Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity.
Identifieur interne : 001119 ( PubMed/Curation ); précédent : 001118; suivant : 001120Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity.
Auteurs : William C. Weldon [États-Unis] ; Maria P. Martin ; Vladimir Zarnitsyn ; Baozhong Wang ; Dimitrios Koutsonanos ; Ioanna Skountzou ; Mark R. Prausnitz ; Richard W. CompansSource :
- Clinical and vaccine immunology : CVI [ 1556-679X ] ; 2011.
Descripteurs français
- KwdFr :
- Analyse de survie, Animaux, Charge virale, Glycoprotéine hémagglutinine du virus influenza (administration et posologie), Glycoprotéine hémagglutinine du virus influenza (immunologie), Immunité muqueuse, Infections à Orthomyxoviridae (), Infections à Orthomyxoviridae (immunologie), Injections intradermiques (), Lymphocytes auxiliaires Th1 (immunologie), Modèles animaux de maladie humaine, Poumon (virologie), Souris, Souris de lignée BALB C, Vaccination (), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (immunologie), Vaccins sous-unitaires (administration et posologie), Vaccins sous-unitaires (immunologie), Vaccins synthétiques (administration et posologie), Vaccins synthétiques (immunologie), Virus de la grippe A (immunologie).
- MESH :
- administration et posologie : Glycoprotéine hémagglutinine du virus influenza, Vaccins antigrippaux, Vaccins sous-unitaires, Vaccins synthétiques.
- immunologie : Glycoprotéine hémagglutinine du virus influenza, Infections à Orthomyxoviridae, Lymphocytes auxiliaires Th1, Vaccins antigrippaux, Vaccins sous-unitaires, Vaccins synthétiques, Virus de la grippe A.
- virologie : Poumon.
- Analyse de survie, Animaux, Charge virale, Immunité muqueuse, Infections à Orthomyxoviridae, Injections intradermiques, Modèles animaux de maladie humaine, Souris, Souris de lignée BALB C, Vaccination.
English descriptors
- KwdEn :
- Animals, Disease Models, Animal, Hemagglutinin Glycoproteins, Influenza Virus (administration & dosage), Hemagglutinin Glycoproteins, Influenza Virus (immunology), Immunity, Mucosal, Influenza A virus (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (immunology), Injections, Intradermal (methods), Lung (virology), Mice, Mice, Inbred BALB C, Orthomyxoviridae Infections (immunology), Orthomyxoviridae Infections (prevention & control), Survival Analysis, Th1 Cells (immunology), Vaccination (methods), Vaccines, Subunit (administration & dosage), Vaccines, Subunit (immunology), Vaccines, Synthetic (administration & dosage), Vaccines, Synthetic (immunology), Viral Load.
- MESH :
- chemical , administration & dosage : Hemagglutinin Glycoproteins, Influenza Virus, Influenza Vaccines, Vaccines, Subunit, Vaccines, Synthetic.
- chemical , immunology : Hemagglutinin Glycoproteins, Influenza Virus, Influenza Vaccines, Vaccines, Subunit, Vaccines, Synthetic.
- immunology : Influenza A virus, Orthomyxoviridae Infections, Th1 Cells.
- methods : Injections, Intradermal, Vaccination.
- prevention & control : Orthomyxoviridae Infections.
- virology : Lung.
- Animals, Disease Models, Animal, Immunity, Mucosal, Mice, Mice, Inbred BALB C, Survival Analysis, Viral Load.
Abstract
The emergence of the swine-origin 2009 influenza pandemic illustrates the need for improved vaccine production and delivery strategies. Skin-based immunization represents an attractive alternative to traditional hypodermic needle vaccination routes. Microneedles (MNs) can deliver vaccine to the epidermis and dermis, which are rich in antigen-presenting cells (APC) such as Langerhans cells and dermal dendritic cells. Previous studies using coated or dissolvable microneedles emphasized the use of inactivated influenza virus or virus-like particles as skin-based vaccines. However, most currently available influenza vaccines consist of solubilized viral protein antigens. Here we test the hypothesis that a recombinant subunit influenza vaccine can be delivered to the skin by coated microneedles and can induce protective immunity. We found that mice vaccinated via MN delivery with a stabilized recombinant trimeric soluble hemagglutinin (sHA) derived from A/Aichi/2/68 (H3) virus had significantly higher immune responses than did mice vaccinated with unmodified sHA. These mice were fully protected against a lethal challenge with influenza virus. Analysis of postchallenge lung titers showed that MN-immunized mice had completely cleared the virus from their lungs, in contrast to mice given the same vaccine by a standard subcutaneous route. In addition, we observed a higher ratio of antigen-specific Th1 cells in trimeric sHA-vaccinated mice and a greater mucosal antibody response. Our data therefore demonstrate the improved efficacy of a skin-based recombinant subunit influenza vaccine and emphasize the advantage of this route of vaccination for a protein subunit vaccine.
DOI: 10.1128/CVI.00435-10
PubMed: 21288996
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001119
Links to Exploration step
pubmed:21288996Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity.</title>
<author><name sortKey="Weldon, William C" sort="Weldon, William C" uniqKey="Weldon W" first="William C" last="Weldon">William C. Weldon</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, 1510 Clifton Road, Atlanta, GA 30322, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, 1510 Clifton Road, Atlanta, GA 30322</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Martin, Maria P" sort="Martin, Maria P" uniqKey="Martin M" first="Maria P" last="Martin">Maria P. Martin</name>
</author>
<author><name sortKey="Zarnitsyn, Vladimir" sort="Zarnitsyn, Vladimir" uniqKey="Zarnitsyn V" first="Vladimir" last="Zarnitsyn">Vladimir Zarnitsyn</name>
</author>
<author><name sortKey="Wang, Baozhong" sort="Wang, Baozhong" uniqKey="Wang B" first="Baozhong" last="Wang">Baozhong Wang</name>
</author>
<author><name sortKey="Koutsonanos, Dimitrios" sort="Koutsonanos, Dimitrios" uniqKey="Koutsonanos D" first="Dimitrios" last="Koutsonanos">Dimitrios Koutsonanos</name>
</author>
<author><name sortKey="Skountzou, Ioanna" sort="Skountzou, Ioanna" uniqKey="Skountzou I" first="Ioanna" last="Skountzou">Ioanna Skountzou</name>
</author>
<author><name sortKey="Prausnitz, Mark R" sort="Prausnitz, Mark R" uniqKey="Prausnitz M" first="Mark R" last="Prausnitz">Mark R. Prausnitz</name>
</author>
<author><name sortKey="Compans, Richard W" sort="Compans, Richard W" uniqKey="Compans R" first="Richard W" last="Compans">Richard W. Compans</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2011">2011</date>
<idno type="RBID">pubmed:21288996</idno>
<idno type="pmid">21288996</idno>
<idno type="doi">10.1128/CVI.00435-10</idno>
<idno type="wicri:Area/PubMed/Corpus">001119</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001119</idno>
<idno type="wicri:Area/PubMed/Curation">001119</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001119</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity.</title>
<author><name sortKey="Weldon, William C" sort="Weldon, William C" uniqKey="Weldon W" first="William C" last="Weldon">William C. Weldon</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, 1510 Clifton Road, Atlanta, GA 30322, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, 1510 Clifton Road, Atlanta, GA 30322</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Martin, Maria P" sort="Martin, Maria P" uniqKey="Martin M" first="Maria P" last="Martin">Maria P. Martin</name>
</author>
<author><name sortKey="Zarnitsyn, Vladimir" sort="Zarnitsyn, Vladimir" uniqKey="Zarnitsyn V" first="Vladimir" last="Zarnitsyn">Vladimir Zarnitsyn</name>
</author>
<author><name sortKey="Wang, Baozhong" sort="Wang, Baozhong" uniqKey="Wang B" first="Baozhong" last="Wang">Baozhong Wang</name>
</author>
<author><name sortKey="Koutsonanos, Dimitrios" sort="Koutsonanos, Dimitrios" uniqKey="Koutsonanos D" first="Dimitrios" last="Koutsonanos">Dimitrios Koutsonanos</name>
</author>
<author><name sortKey="Skountzou, Ioanna" sort="Skountzou, Ioanna" uniqKey="Skountzou I" first="Ioanna" last="Skountzou">Ioanna Skountzou</name>
</author>
<author><name sortKey="Prausnitz, Mark R" sort="Prausnitz, Mark R" uniqKey="Prausnitz M" first="Mark R" last="Prausnitz">Mark R. Prausnitz</name>
</author>
<author><name sortKey="Compans, Richard W" sort="Compans, Richard W" uniqKey="Compans R" first="Richard W" last="Compans">Richard W. Compans</name>
</author>
</analytic>
<series><title level="j">Clinical and vaccine immunology : CVI</title>
<idno type="eISSN">1556-679X</idno>
<imprint><date when="2011" type="published">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Disease Models, Animal</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus (administration & dosage)</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus (immunology)</term>
<term>Immunity, Mucosal</term>
<term>Influenza A virus (immunology)</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Injections, Intradermal (methods)</term>
<term>Lung (virology)</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Orthomyxoviridae Infections (immunology)</term>
<term>Orthomyxoviridae Infections (prevention & control)</term>
<term>Survival Analysis</term>
<term>Th1 Cells (immunology)</term>
<term>Vaccination (methods)</term>
<term>Vaccines, Subunit (administration & dosage)</term>
<term>Vaccines, Subunit (immunology)</term>
<term>Vaccines, Synthetic (administration & dosage)</term>
<term>Vaccines, Synthetic (immunology)</term>
<term>Viral Load</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Analyse de survie</term>
<term>Animaux</term>
<term>Charge virale</term>
<term>Glycoprotéine hémagglutinine du virus influenza (administration et posologie)</term>
<term>Glycoprotéine hémagglutinine du virus influenza (immunologie)</term>
<term>Immunité muqueuse</term>
<term>Infections à Orthomyxoviridae ()</term>
<term>Infections à Orthomyxoviridae (immunologie)</term>
<term>Injections intradermiques ()</term>
<term>Lymphocytes auxiliaires Th1 (immunologie)</term>
<term>Modèles animaux de maladie humaine</term>
<term>Poumon (virologie)</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Vaccination ()</term>
<term>Vaccins antigrippaux (administration et posologie)</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Vaccins sous-unitaires (administration et posologie)</term>
<term>Vaccins sous-unitaires (immunologie)</term>
<term>Vaccins synthétiques (administration et posologie)</term>
<term>Vaccins synthétiques (immunologie)</term>
<term>Virus de la grippe A (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Hemagglutinin Glycoproteins, Influenza Virus</term>
<term>Influenza Vaccines</term>
<term>Vaccines, Subunit</term>
<term>Vaccines, Synthetic</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Hemagglutinin Glycoproteins, Influenza Virus</term>
<term>Influenza Vaccines</term>
<term>Vaccines, Subunit</term>
<term>Vaccines, Synthetic</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Glycoprotéine hémagglutinine du virus influenza</term>
<term>Vaccins antigrippaux</term>
<term>Vaccins sous-unitaires</term>
<term>Vaccins synthétiques</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Glycoprotéine hémagglutinine du virus influenza</term>
<term>Infections à Orthomyxoviridae</term>
<term>Lymphocytes auxiliaires Th1</term>
<term>Vaccins antigrippaux</term>
<term>Vaccins sous-unitaires</term>
<term>Vaccins synthétiques</term>
<term>Virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A virus</term>
<term>Orthomyxoviridae Infections</term>
<term>Th1 Cells</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Injections, Intradermal</term>
<term>Vaccination</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Lung</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Disease Models, Animal</term>
<term>Immunity, Mucosal</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Survival Analysis</term>
<term>Viral Load</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Analyse de survie</term>
<term>Animaux</term>
<term>Charge virale</term>
<term>Immunité muqueuse</term>
<term>Infections à Orthomyxoviridae</term>
<term>Injections intradermiques</term>
<term>Modèles animaux de maladie humaine</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Vaccination</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The emergence of the swine-origin 2009 influenza pandemic illustrates the need for improved vaccine production and delivery strategies. Skin-based immunization represents an attractive alternative to traditional hypodermic needle vaccination routes. Microneedles (MNs) can deliver vaccine to the epidermis and dermis, which are rich in antigen-presenting cells (APC) such as Langerhans cells and dermal dendritic cells. Previous studies using coated or dissolvable microneedles emphasized the use of inactivated influenza virus or virus-like particles as skin-based vaccines. However, most currently available influenza vaccines consist of solubilized viral protein antigens. Here we test the hypothesis that a recombinant subunit influenza vaccine can be delivered to the skin by coated microneedles and can induce protective immunity. We found that mice vaccinated via MN delivery with a stabilized recombinant trimeric soluble hemagglutinin (sHA) derived from A/Aichi/2/68 (H3) virus had significantly higher immune responses than did mice vaccinated with unmodified sHA. These mice were fully protected against a lethal challenge with influenza virus. Analysis of postchallenge lung titers showed that MN-immunized mice had completely cleared the virus from their lungs, in contrast to mice given the same vaccine by a standard subcutaneous route. In addition, we observed a higher ratio of antigen-specific Th1 cells in trimeric sHA-vaccinated mice and a greater mucosal antibody response. Our data therefore demonstrate the improved efficacy of a skin-based recombinant subunit influenza vaccine and emphasize the advantage of this route of vaccination for a protein subunit vaccine.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21288996</PMID>
<DateCompleted><Year>2011</Year>
<Month>07</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1556-679X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>18</Volume>
<Issue>4</Issue>
<PubDate><Year>2011</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>Clinical and vaccine immunology : CVI</Title>
<ISOAbbreviation>Clin. Vaccine Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity.</ArticleTitle>
<Pagination><MedlinePgn>647-54</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/CVI.00435-10</ELocationID>
<Abstract><AbstractText>The emergence of the swine-origin 2009 influenza pandemic illustrates the need for improved vaccine production and delivery strategies. Skin-based immunization represents an attractive alternative to traditional hypodermic needle vaccination routes. Microneedles (MNs) can deliver vaccine to the epidermis and dermis, which are rich in antigen-presenting cells (APC) such as Langerhans cells and dermal dendritic cells. Previous studies using coated or dissolvable microneedles emphasized the use of inactivated influenza virus or virus-like particles as skin-based vaccines. However, most currently available influenza vaccines consist of solubilized viral protein antigens. Here we test the hypothesis that a recombinant subunit influenza vaccine can be delivered to the skin by coated microneedles and can induce protective immunity. We found that mice vaccinated via MN delivery with a stabilized recombinant trimeric soluble hemagglutinin (sHA) derived from A/Aichi/2/68 (H3) virus had significantly higher immune responses than did mice vaccinated with unmodified sHA. These mice were fully protected against a lethal challenge with influenza virus. Analysis of postchallenge lung titers showed that MN-immunized mice had completely cleared the virus from their lungs, in contrast to mice given the same vaccine by a standard subcutaneous route. In addition, we observed a higher ratio of antigen-specific Th1 cells in trimeric sHA-vaccinated mice and a greater mucosal antibody response. Our data therefore demonstrate the improved efficacy of a skin-based recombinant subunit influenza vaccine and emphasize the advantage of this route of vaccination for a protein subunit vaccine.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weldon</LastName>
<ForeName>William C</ForeName>
<Initials>WC</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, 1510 Clifton Road, Atlanta, GA 30322, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Martin</LastName>
<ForeName>Maria P</ForeName>
<Initials>MP</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zarnitsyn</LastName>
<ForeName>Vladimir</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Baozhong</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y"><LastName>Koutsonanos</LastName>
<ForeName>Dimitrios</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Skountzou</LastName>
<ForeName>Ioanna</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y"><LastName>Prausnitz</LastName>
<ForeName>Mark R</ForeName>
<Initials>MR</Initials>
</Author>
<Author ValidYN="Y"><LastName>Compans</LastName>
<ForeName>Richard W</ForeName>
<Initials>RW</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>AI074579</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>EB006369</GrantID>
<Acronym>EB</Acronym>
<Agency>NIBIB NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 EB006369-03</GrantID>
<Acronym>EB</Acronym>
<Agency>NIBIB NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>U01 EB012495</GrantID>
<Acronym>EB</Acronym>
<Agency>NIBIB NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 EB006369-01A1</GrantID>
<Acronym>EB</Acronym>
<Agency>NIBIB NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 EB006369-04</GrantID>
<Acronym>EB</Acronym>
<Agency>NIBIB NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 EB006369</GrantID>
<Acronym>EB</Acronym>
<Agency>NIBIB NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>U01 EB012495-01</GrantID>
<Acronym>EB</Acronym>
<Agency>NIBIB NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 EB006369-02</GrantID>
<Acronym>EB</Acronym>
<Agency>NIBIB NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>U01 AI074579</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2011</Year>
<Month>02</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Clin Vaccine Immunol</MedlineTA>
<NlmUniqueID>101252125</NlmUniqueID>
<ISSNLinking>1556-679X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019267">Hemagglutinin Glycoproteins, Influenza Virus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D022223">Vaccines, Subunit</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019267" MajorTopicYN="N">Hemagglutinin Glycoproteins, Influenza Virus</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018928" MajorTopicYN="N">Immunity, Mucosal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007271" MajorTopicYN="N">Injections, Intradermal</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009976" MajorTopicYN="N">Orthomyxoviridae Infections</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018417" MajorTopicYN="N">Th1 Cells</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D022223" MajorTopicYN="N">Vaccines, Subunit</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year>
<Month>2</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2011</Year>
<Month>2</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2011</Year>
<Month>7</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">21288996</ArticleId>
<ArticleId IdType="pii">CVI.00435-10</ArticleId>
<ArticleId IdType="doi">10.1128/CVI.00435-10</ArticleId>
<ArticleId IdType="pmc">PMC3122571</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>PLoS One. 2010;5(5):e10645</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20498717</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Invest Dermatol. 2010 May;130(5):1345-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20107482</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2010 Aug;84(15):7760-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20484519</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2010 Aug;16(8):915-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20639891</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2010;5(9). pii: e12466. doi: 10.1371/journal.pone.0012466</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20824188</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2000 May;74(10):4746-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10775613</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2000 Jun;74(11):4999-5005</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10799573</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharm Res. 2002 Jan;19(1):63-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11837701</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 2002 Aug 5;196(3):303-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12163559</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2003 Feb 20;421(6925):852-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12594515</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2003 Jun 20;21(21-22):2830-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12798624</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Leukoc Biol. 2004 Feb;75(2):163-89</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14525967</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Kidney Dis. 2004 May;43(5):910-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15112182</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2004 Aug 1;173(3):1978-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15265932</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Hyg (Lond). 1972 Dec;70(4):767-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4509641</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Invest Dermatol. 1983 Jun;80 Suppl:12s-16s</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6602189</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 1999 Apr;37(4):937-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10074505</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2004 Nov 25;351(22):2295-301</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15525714</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Immunol. 1989 Sep;1(1):55-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15630959</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2005 Apr 8;23(20):2565-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15780438</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Immunol. 2005 Aug;17(4):273-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15953735</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2006 Jan 5;439(7072):38-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16397490</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2006 Aug 28;24(35-36):6110-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16766095</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Control Release. 2007 Feb 12;117(2):227-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17169459</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Vaccine Immunol. 2007 Apr;14(4):375-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17329444</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Immunopathol. 2007 Apr;29(1):15-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17621951</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2008 Apr 25;283(17):11382-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18252707</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Protoc Immunol. 2001 May;Chapter 19:Unit 19.11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18432752</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin J Pain. 2008 Sep;24(7):585-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18716497</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Biotechnol. 2008 Nov;26(11):1261-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18997767</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2009;4(3):e4773</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19274084</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Immunol. 2009 Apr;10(4):385-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19252490</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2009 May 18;27(23):3063-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19428920</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2009 May 12;106(19):7968-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19416832</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2009;4(9):e7152</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19779615</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Immunol. 2009 Oct;9(10):679-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19763149</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2009 Nov 16;27(49):6932-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19761836</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2009 Nov 27;27(51):7214-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19925956</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2010;5(2):e9161</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20161790</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drugs Aging. 2010 Jul 1;27(7):597-605</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20583853</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001119 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001119 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= PandemieGrippaleV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:21288996 |texte= Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:21288996" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a PandemieGrippaleV1
![]() | This area was generated with Dilib version V0.6.34. | ![]() |